Literature DB >> 1170648

Complications of heparin therapy.

A S Gervin.   

Abstract

Currently, heparin therapy is rarely extended for periods required for the onset of chronic complications. Thus, alopecia and skeletal defects are infrequently encountered. However, during pregnancy, prolonged therapy with heparin may be used. Heparin does not cross the placental barrier, whereas the warfarin class of anticoagulants is freely transported across the barrier. Thus, if extended anticoagulation is required during pregnancy, heparin is preferred to provide maternal anticoagulation while protecting against fetal hemorrhage. Hemorrhage, the most frequent and most feared complication of heparin therapy, does not occur spontaneously in all patients receiving large doses of heparin. However, in certain populations, hemorrhage must be anticipated and appropriate modifications made in the heparin dosage. Elderly women, persons with thrombocytopenia or drug induced platelet dysfunction, or persons who have undergone recent surgical treatment or trauma are sensitive to standard heparin dosages and may bleed during heparin therapy. In these situations, the initial heparin dosage must be appropriately decreased and subsequent dosages carefully determined by frequently monitored coagulation studies. a well maintained, functional coagulation laboratory is imperative in these situations. By careful monitoring of coagulation parameters and by the selection of the smallest effective heparin dosage, complications can be minimized. The clinical cognizance of heparin induced thrombocytopenia is increasing. This disorder must be considered when hemorrhage and low platelet numbers appear during heparin therapy. Discontinuance of heparin therapy causes a rapid increase in platelet counts and diminution of bleeding. The indiscriminate use of protamine sulfate to neutralize heparin must be discouraged. One must resist the temptation to administer multiple extra doses of protamine to assure achievement of hemostasis. The precise dosage of protamine sulfate calculated to neutralize a given heparin dosage must be used. Additional doses of protamine must be determined by coagulation studies, such as whole blood clotting time, protamine titration test, or thrombin time with toluidine blue correction. If proper attention is directed to the dosage of protamine, relative to heparin, the complications of neutralization rarely will occur. Heparin is a basic drug in the armamentarium of the contemporary surgeon. Successful clinical use of heparin requires fundamental knowledge of coagulation mechanisms, the manner in which heparin alters these mechanisms, and the factors which predispose to complications. The complications of heparin therapy can be minimized by strictest attention to selection of initial dosage and by careful subsequent determination of the precise coagulation status of the patient.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1170648

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  8 in total

1.  Photochemical Preparation of a Novel Low Molecular Weight Heparin.

Authors:  Kyohei Higashi; Saori Hosoyama; Asami Ohno; Sayaka Masuko; Bo Yang; Eric Sterner; Zhenyu Wang; Robert J Linhardt; Toshihiko Toida
Journal:  Carbohydr Polym       Date:  2012-02-01       Impact factor: 9.381

Review 2.  Chemoenzymatic synthesis of the next generation of ultralow MW heparin therapeutics.

Authors:  Sayaka Masuko; Robert J Linhardt
Journal:  Future Med Chem       Date:  2012-03       Impact factor: 3.808

3.  Ozonolysis of the double bond of the unsaturated uronate residue in low-molecular-weight heparin and K5 heparosan.

Authors:  Sayaka Masuko; Kyohei Higashi; Zhenyu Wang; Ujjwal Bhaskar; Anne Marie Hickey; Fuming Zhang; Toshihiko Toida; Jonathan S Dordick; Robert J Linhardt
Journal:  Carbohydr Res       Date:  2011-06-22       Impact factor: 2.104

4.  An immobilized microbial heparinase for blood deheparinization.

Authors:  R J Linhardt; C L Cooney; D Tapper; C A Zannetos; A K Larsen; R Langer
Journal:  Appl Biochem Biotechnol       Date:  1984-02       Impact factor: 2.926

5.  Optimized labeling of bone marrow mesenchymal cells with superparamagnetic iron oxide nanoparticles and in vivo visualization by magnetic resonance imaging.

Authors:  Ana Luiza M Torres; Henrique M P Nunes; Juliana A Passipieri; Linda A Jelicks; Emerson L Gasparetto; David C Spray; Antonio C Campos de Carvalho; Rosalia Mendez-Otero
Journal:  J Nanobiotechnology       Date:  2011-02-09       Impact factor: 10.435

6.  New "multicolor" polypeptide diamagnetic chemical exchange saturation transfer (DIACEST) contrast agents for MRI.

Authors:  Michael T McMahon; Assaf A Gilad; Marco A DeLiso; Stacey M Cromer Berman; Jeff W M Bulte; Peter C M van Zijl
Journal:  Magn Reson Med       Date:  2008-10       Impact factor: 4.668

7.  Labeling stem cells with superparamagnetic iron oxide nanoparticles: analysis of the labeling efficacy by microscopy and magnetic resonance imaging.

Authors:  Ana Luiza Machado Torres; Linda Jelicks; Antonio Carlos Campos de Carvalho; David C Spray; Rosalia Mendez-Otero
Journal:  Methods Mol Biol       Date:  2012

8.  Evaluating the effect of ultrasmall superparamagnetic iron oxide nanoparticles for a long-term magnetic cell labeling.

Authors:  Saeed Shanehsazzadeh; Mohammad Ali Oghabian; Barry J Allen; Massoud Amanlou; Afshin Masoudi; Fariba Johari Daha
Journal:  J Med Phys       Date:  2013-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.